Quick Answer
IONIS PHARMACEUTICALS INC reported Operating Income Loss of -$381.68 million for the year ending 2025.
- IONIS PHARMACEUTICALS INC showed an increase of +19.7% in Operating Income Loss from 2024 to 2025.
- This data is from IONIS PHARMACEUTICALS INC's annual report (Form 10-K), filed with the SEC on February 26, 2026.
- XBRL data for this metric is available from 2008 to 2025 (18 years of filings). Earlier data may not exist in machine-readable XBRL format as companies adopted electronic filing at different times.
- Quarterly values from 10-Q filings: Q2 2014: -$6.65 million | Q3 2014: -$21.49 million | Q4 2014: $10.08 million | Q1 2015: -$9.33 million | Q2 2015: $44.65 million | Q3 2015: -$48.14 million | Q4 2015: -$62.94 million | Q1 2016: -$54.65 million | Q2 2016: -$48.93 million | Q3 2016: $16.11 million | Q4 2016: $41.16 million | Q1 2017: $19.49 million | Q2 2017: $6.45 million | Q3 2017: $11.31 million | Q4 2017: -$6.20 million | Q1 2018: -$3.30 million | Q2 2018: -$50.28 million | Q3 2018: -$18.57 million | Q4 2018: $10.78 million | Q1 2019: $121.54 million | Q2 2019: -$18.83 million | Q3 2019: $2.52 million | Q4 2019: $260.65 million | Q1 2020: -$61.13 million | Q2 2020: -$51.75 million | Q3 2020: -$36.54 million | Q4 2020: -$22.66 million | Q1 2021: -$91.97 million | Q2 2021: -$72.97 million | Q3 2021: -$85.85 million | Q4 2021: $220.60 million | Q1 2022: -$57.50 million | Q2 2022: -$85.51 million | Q3 2022: -$59.15 million | Q4 2022: -$208.02 million | Q1 2023: -$114.15 million | Q2 2023: -$90.20 million | Q3 2023: -$143.27 million | Q4 2023: -$6.12 million | Q1 2024: -$149.51 million | Q2 2024: -$66.09 million | Q3 2024: -$148.66 million | Q4 2024: -$110.82 million | Q1 2025: -$146.86 million | Q2 2025: $139.82 million | Q3 2025: -$160.18 million | Q4 2025: -$214.46 million.
- Over the full 18 years of available data (2008 to 2025), IONIS PHARMACEUTICALS INC's Operating Income Loss has declined by 2,822.5%.
- Historical annual values: Fiscal year 2025: -$381.68 million | Fiscal year 2024: -$475.08 million | Fiscal year 2023: -$353.73 million | Fiscal year 2022: -$410.19 million | Fiscal year 2021: -$30.19 million | Fiscal year 2020: -$172.08 million | Fiscal year 2019: $365.88 million | Fiscal year 2018: -$61.37 million | Fiscal year 2017: $31.05 million | Fiscal year 2016: -$20.16 million | Fiscal year 2015: -$75.76 million | Fiscal year 2014: -$47.73 million | Fiscal year 2013: -$51.67 million | Fiscal year 2012: -$68.92 million | Fiscal year 2011: -$71.10 million | Fiscal year 2010: -$48.36 million | Fiscal year 2009: -$27.54 million | Fiscal year 2008: -$13.06 million.
- Data sourced from SEC EDGAR public filings as of August 9, 2026.
Last verified: